Autolus Therapeutics

Autolus Therapeutics

Biotechnology

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer

About us

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Website
http://www.autolus.com
Industry
Biotechnology
Company size
501-1,000 employees
Headquarters
London
Type
Public Company
Founded
2014

Locations

Employees at Autolus Therapeutics

Updates

Similar pages

Browse jobs

Funding

Autolus Therapeutics 10 total rounds

Last Round

Post IPO equity

US$ 350.0M

See more info on crunchbase